Scholarlink

ESA hyporesponsiveness makes it difficult for clinical treatment of renal anemia. In this case, we reported a 70-year-old male patient undergoing peritoneal dialysis with moderate to severe anemia. His hemoglobin gradually increased to relatively normal levels after receiving a high dose of EPO. However, severe anemia occurred again after 10 months’ treatment. On the basis of anemia recurrence and bone marrow aspiration results, the patient was diagnosed with EPO-induced PRCA and his medication regimen was switched from EPO to Roxadustat, along with cyclosporine and WuZhi capsules for immunotherapy, which effectively and safely corrected anemia. This case suggest that EPO-induced PRCA should be considered when progressive anemia occurs during the use of EPO, and Roxadustat with immunotherapy co-administration would be an effective treatment for these patients.

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Treatment of Erythropoietin-Induced Pure Red Cell Aplastic Anemia

  • 章节

  • 出版模式：

    开放获取

  • 发表日期：

    2025年

查看全文
  • Jia-Feng Liu,
  • Li-Jun Mou,
  • Kun-Ling Ma

摘要

ESA hyporesponsiveness makes it difficult for clinical treatment of renal anemia. In this case, we reported a 70-year-old male patient undergoing peritoneal dialysis with moderate to severe anemia. His hemoglobin gradually increased to relatively normal levels after receiving a high dose of EPO. However, severe anemia occurred again after 10 months’ treatment. On the basis of anemia recurrence and bone marrow aspiration results, the patient was diagnosed with EPO-induced PRCA and his medication regimen was switched from EPO to Roxadustat, along with cyclosporine and WuZhi capsules for immunotherapy, which effectively and safely corrected anemia. This case suggest that EPO-induced PRCA should be considered when progressive anemia occurs during the use of EPO, and Roxadustat with immunotherapy co-administration would be an effective treatment for these patients.